SLC5A2 and thyrotoxicosis: The findings in this case indicate that thyrotoxicosis may amplify the risk of DKA in the presence of the ketogenic state triggered by SGLT2 inhibitor therapy, even when the thyrotoxicosis does not reach the severity of thyroid crisis, due to the interplay with the lipolytic metabolic changes induced by thyrotoxicosis.